Cover Feature: Identification of Novel Oxazolo[5,4‐ d ]pyrimidines as IL‐33 Inhibitors for Immuno‐Oncology Therapy (ChemBioChem 6/2026)

View at publisher Summarise with VIRAT
Authors: Young‐Hoon Kim, Kyeong Hee Hong, Minjoo Ko, Eunji Kim, Bong‐geun Ahn, S. Son, Young Ho Jeon, Sang‐Jun Ha, Taebo Sim
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

A rationally designed KYH1942 disrupts the IL-33/ST2 signaling axis by binding to IL-33. IL-33 (pink) engages the ST2 receptor on Treg cells (green), leading to activation of Treg cells characterized by elevated expression of FOXP3. The cover illustration depicts suppression of this pathway by an IL-33–ST2 PPI inhibitor (KYH1942, blue sticks), resulting in reduced FOXP3 expression and diminished Treg cell activation (dark brown). A magnified view highlights KYH1942 occupying a hydrophobic pocket of IL-33, illustrating molecular basis for blockade of the IL-33/ST2 interaction. More details can be found in the Research Article by Sang-Jun Ha, Taebo Sim, and co-workers (DOI: 10.1002/cbic.202500417).

Fields of Study & Subjects

IL-33 ST2 and ILC Pathways Cytokine Signaling Pathways and Interactions Heterocyclic Compound Synthesis and Bioactivity

Publication details

Journal / source
ChemBioChem
Volume
27
Issue
6
Publication date
25 March 2026
Language
EN